KOPKoppers Holdings Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−11% a year). Little growth is priced in even as revenue fell 4% a year over three years, potential value, or a value trap.
In its normal range: P/E 10.2 vs a 11.0 median over 38 quarters (−7% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What KOP's price assumes
Koppers Holdings Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.40× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 16%
Free cash flow yield · Specialty Chemicals median 4.7%
- Growth the price implies
- −11%
Growth the price implies · The price pays for −11% free cash flow growth a year for a decade; revenue has grown −3.5% a year over the last three.
- Price / book
- 1.35
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 1.35
- EV / EBIToperating margin −2.2%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 0.92
- Free cash flow, trailing twelve months
- $139M
- Market capitalisation
- $851M
- 3-year revenue growth
- −3.5%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Specialty Chemicals
Ranks #22 of 33 by RyuScore